Moderna shares soar on melanoma drug trial success

Only left-leaning outlets are covering this.

How each outlet headlined it

• Investing.com Stocks

  Moderna shares soar on melanoma drug trial success
• Investor's Business Daily right

  Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday. The post Moderna Skyrockets Over 60%, Merck Jumps On Late-Stage Cancer Vaccine Trial Win appeared first on Investor's Business Daily.
• Bloomberg center

  Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
• Medical Xpress

  U.S. pharmaceutical firms Merck and Moderna announced encouraging results Wednesday from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.
• The Hill center

  An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…
• Bloomberg News center

  Moderna and Merck said their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial.